Axelar AB (Axelar) is a privately held biotechnology company. It is principally engaged in research and development as well as the production of Cancer / IGF inhibitor pharmaceuticals. The company works with a mission to develop innovative small-molecule compounds which inhibit the IGF-1 receptor for treatment of IGF-1 receptor-dependent diseases. AXL1717 is the lead product of the company, which is undergoing phase I/II clinical trails for effective use against tumors, prostate cancer and breast cancer, malignant melanoma, glioblastoma (intracerebral implants), sarcoma and multiple myeloma. Axelar is headquartered in Stockholm, Sweden.